Compare · ARGX vs IPSC
ARGX vs IPSC
Side-by-side comparison of argenx SE (ARGX) and Century Therapeutics Inc. (IPSC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and IPSC operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $50.79B, about 203.2x IPSC ($249.9M).
- Over the past year, ARGX is down 1.9% and IPSC is up 150.4% - IPSC leads by 152.2 points.
- ARGX has been more active in the news (6 items in the past 4 weeks vs 3 for IPSC).
- ARGX has more recent analyst coverage (25 ratings vs 14 for IPSC).
- Company
- argenx SE
- Century Therapeutics Inc.
- Price
- $819.19-3.28%
- $1.38-8.00%
- Market cap
- $50.79B
- $249.9M
- 1M return
- -17.73%
- -26.60%
- 1Y return
- -1.87%
- +150.36%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2021
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 14
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Century Therapeutics Inc.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest IPSC
- Century Therapeutics to Attend 2026 Jefferies Global Healthcare Conference in London
- Century Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026
- Officer Russotti Gregory sold $4,993 worth of shares (2,587 units at $1.93), decreasing direct ownership by 0.51% to 509,198 units (SEC Form 4) to satisfy tax liability
- SVP Finance & Operations Carr Douglas sold $3,200 worth of shares (1,658 units at $1.93), decreasing direct ownership by 0.33% to 502,907 units (SEC Form 4) to satisfy withholding obligation
- President and CEO Pfeiffenberger Brent covered exercise/tax liability with 13,850 shares, decreasing direct ownership by 0.38% to 3,633,839 units (SEC Form 4) (withholding tax)
- SEC Form 4 filed by Director Truitt Joseph
- SEC Form 3 filed by new insider Truitt Joseph
- President and CEO Pfeiffenberger Brent covered exercise/tax liability with 463 shares, decreasing direct ownership by 0.01% to 3,633,839 units (SEC Form 4) to satisfy tax liability
- SVP Finance & Operations Carr Douglas sold $521 worth of shares (254 units at $2.05), decreasing direct ownership by 0.05% to 504,565 units (SEC Form 4) to cover withholding tax